Transplantation in HIV+ Recipients Ron Shapiro, M.D. THOMAS E. STARZL TRANSPLANTATION INSTITUTE UNIVERSITY OF PITTSBURGH.

Slides:

Advertisements

Similar presentations

Saleem Bharmal 9/23/08.  Association between HIV and renal disease first reported in 1984  HIV-1 seropositive patients  Renal syndrome characterized.

Advertisements

Chapter 7: Pediatric ESRD 2014 A NNUAL D ATA R EPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE.

The Role of Comorbidity in Determining Outcomes in HIV Amy C. Justice, MD, PhD Grand Rounds University of Pittsburgh School of Medicine February 1, 2002.

Supporting the Neonatal and Pediatric Donor Breakout Session A Presenters: Jeffrey Johnson, MD, LAC + USC Medical Center Mudit Mather, MD, Loma Linda University.

Prolonged Diabetes Reversal after intraportal xenotransplantation of wild-type porcine islets in immunosuppressed nonhuman primates Hering et al, Nature.

Superior outcomes in HIV-positive kidney transplant patients compared to HCV-infected or HIV/HCV co-infected recipients Deirdre Sawinski MD, Kimberly A.

HEART TRANSPLANTATION Pediatric Recipients ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

Slide Seminar Drugs and Kidney Case 3 Heinz Regele Department of Pathology.

Role of Antiretroviral Therapy, Viral Replication, and HIV Infection in Atherosclerosis Priscilla Y. Hsue, Peter W. Hunt, Jeffrey N. Martin, Amanda Schnell,

Cost-effectiveness of different starting criteria of antiretroviral therapy in Mexico. Caro Y., Colchero A., Valencia A., Bautista-Arredondo S., Sierra.

Author(s): Silas P. Norman, M.D., 2009 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution–Noncommercial–Share.

Optimizing lung transplant outcomes in the adult and pediatric patient. Cynthia S. Herrington, MD Associate Professor of Surgery Keck School of Medicine.

HEART-LUNG TRANSPLANTATION Overall ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

Living Donor Kidneys in PAK 2/11 USA Primary DD Pancreas Transplants 1/1/1988 – 12/31/2010.

International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPACT) Group PROMISE (BREAST FEEDING) 1077 AAHU STC 2013 Group 2 Cedric Sturdevant,

Renal Transplantation for HIV/HCV Co-infected Patients Solid Organ Transplantation and People With HIV: Ethics and Policy Conference David Oldach & Robert.

David C. Mulligan, MD, FACS

CORR Report, 2012: CST Annual General Meeting S. Joseph Kim, MD, PhD, FRCPC Vice President, CORR Board of Directors Friday, February 24,

HIV Organ Policy Equity (HOPE) Act Research Criteria: follow-up discussion Advisory Committee on Organ Transplantation April 13, 2015.

LUNG TRANSPLANTATION Pediatric Recipients ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

CHRONIC KIDNEY DISEASE National Healthcare Quality and Disparities Report Chartbook on Effective Treatment.

Table 5.1.1: Stock and Flow of Renal Transplantation, Year New transplant patients

PATIENT-GRAFT SURVIVAL ANALYSIS IN KIDNEY TRASPLANT WITH DECEASED DONOR IN CHILDREN IN ARGENTINA Bisigniano Liliana MD., López-Rivera Arturo.

Hepatitis C+ Recipients: Considerations for Exclusion Emily A. Blumberg, M.D.

Study of cytokine gene polymorphism and graft outcome in live-donor kidney transplantation By Rashad Hassan MD Amgad El-Agroudy, Ahmad Hamdy, Amani Mostafa.

The Expanded Criteria Donors in Kidney Transplantation: 3 Years Experience FAM Shaheen, B. Al-Attar, MZ Souqiyyeh, J.E Cillo, A. Al Sayyari.

Neurocognitive Impairment in HIV-Infected Subjects on HAART: Prevalence and Associations Kevin Robertson *1, Kunling Wu 2, Thomas Parsons 1, Ron Ellis.

I. Jean Davis, PhD, PA, AAHIVS Manager - Clinical Services Desert AIDS Project.

INTRODUCTION Evaluation of Outcomes in Patients Starting Antiretroviral Therapy During Hospitalization Leigh E. Efird, PharmD 1, Manish Patel, PharmD 1,

M ORNING R EPORT February 17, R ENAL T RANSPLANTS Most frequent transplant 45% of all pediatric transplants 7% of renal transplants ≤ 17y 3 year.

History of Opportunistic Complications: Should This Remain An Exclusionary Criterion? Kathleen E. Squires, M.D. Associate Professor of Medicine Keck School.

Glomerular lesions in HIV-1-infected patients: evolution from 1996 to 2007 on 88 consecutive renal biopsies. Clara Flateau, François-Xavier Lescure, Emmanuelle.

Ethics and Policy Conference Day One Summary. Goals of the Meeting Educate people about the status of various protocol decisions Define areas where we.

HEART TRANSPLANTATION Pediatric Recipients 2014 JHLT Oct; 33(10):

Mary Lawrence Hicks, FNP Positive Health Program October 21, 2010.

2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 8: Pediatric ESRD.

2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 7: Transplantation.

Transplantation in HIV Michelle Roland, MD Assistant Professor of Medicine UCSF Positive Health Program at SFGH.

First Multivisceral Transplant following Successful Anti-Retroviral Therapy in HIV-Infected Patient with Short Gut Syndrome A Khanna,C Koval,A Pallotta,B.

Addenbrooke’s Hospital Rosie Hospital INTRODUCTION The cumulative incidence of chronic renal impairment in intestinal transplantation is 0.25 at 72 months;

ORGAN TRANSPLANTATION: PERSONS WITH DETECTABLE HIV VIRAL LOAD Margaret Ragni, MD University of Pittsburgh.

Strategies for Management of Antiretroviral Therapy Study Wafaa El-Sadr and James Neaton for the SMART Study Team.

Open-label W24 ≥ 18 years Chronic HCV infection All genotypes HCV RNA ≥ 10,000 IU/ml Liver transplantation months earlier Child Pugh ≤ 7 and MELD.

TM RAPAMUNE ® O-1 RAPAMUNE ® Overview John F. Neylan, MD Vice President, Transplantation Immunology Clinical Research and Development Wyeth-Ayerst Research.

HEART-LUNG TRANSPLANTATION Pediatric Recipients 2015 JHLT Oct; 34(10):

Figure 2: Trends in currently prescribed antiretroviral therapy % prescribed HAART increased from 74% to 83% Trends in ART use, HIV viral load, and CD4.

Thymoglobulin: An Overview of Its Performance in Clinical Trials as an Agent for the Induction Therapy Reference: Osama Gaber A, Knight RJ, Patel S, et.

Liver transplantation for HCV infection R3 양 인 호 /Prof 김 병 호.

Journal Club Leona Isabella von Köckritz.

Acute Renal Failure in HIV- Infected Individuals Greatly Increases Risk for In-Hospital Mortality Slideset on: Wyatt CM, Arons RR, Klotman PE, Klotman.

Stefanie L. Drahuschak University of Pittsburgh School of Pharmacy PharmD Candidate 2014.

HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.

CD4 trajectory among HIV positive patients receiving HAART in a large East African HIV care centre Agnes N. Kiragga 1, Beverly Musick 2 Ronald Bosch, Ann.

HIV-associated CKD (HIV-CKD) Studies from Africa have shown a variable prevalence of renal disease in HIV, ranging from 6% to 45% : (6% in SA, 38% in.

United States Organ Transplantation SRTR & OPTN Annual Data Report, 2011 Kidney.

Hypomagnesemia and the Risk of New-Onset Diabetes Mellitus after Kidney Transplantation J Am Soc Nephrol 27: 1793–1800, 2016 순천향 대학병원 신장내과 강혜란.

Kidney Graft Survival Rates do not improve by era: the impact of factor “Age” E. Bertoni MD, A. Larti MD, G. Rosso MD and M. Salvadori MD Renal Unit –

World Kidney Day 2016: Kidney Disease & Children

2016 Annual Data Report, Vol 2, ESRD, Ch 8

2016 Annual Data Report, Vol 2, ESRD, Ch 6

Kidney disease in HIV-positive patients

HCV & liver transplantation

Number of Grafts Performed by Country

Liver Transplantation: 50 years

Chronic Kidney Disease in HIV Infection: An Urban Epidemic

An Observational Study on Thrombotic Microangiopathy in Renal Transplant Recipients - A Tertiary Care Centre Experience. Dr Sarang Vijayan Senior Resident.

Viral Hepatitis in Liver Transplantation

Update in Nephrology 2013 Does AKI lead to ESRD?

Worldwide incidence of ESRD figure 12.1, per million population

Presentation transcript:

Transplantation in HIV+ Recipients Ron Shapiro, M.D. THOMAS E. STARZL TRANSPLANTATION INSTITUTE UNIVERSITY OF PITTSBURGH

Thomas E. Starzl Transplantation Institute Transplantation in HIV+ Recipients Prior to HIV+ = AIDS Transplantation formally contraindicated Median survival for HIV+ patients on dialysis – 10 months.

Thomas E. Starzl Transplantation Institute Transplantation in HIV+ Recipients Tzakis – Pittsburgh Experience N – 25 Pediatric – Infected Pretransplantation 14 - Infected Peritransplantation PatientsSurvivors Liver 15 7(43%) Kidney 5 4(80%) Heart 5 2(40%)

Thomas E. Starzl Transplantation Institute Transplantation in HIV+ Recipients Pediatric – 70% Survival One Death from AIDS Adult – 40% Survival 5 Deaths from AIDS However, survival not statistically worse than in HIV- recipients.

Thomas E. Starzl Transplantation Institute Transplantation in HIV+ Recipients Minnesota – 1990 N – 21, 5 local and 16 from literature Kidney – 11 Liver – 10

Thomas E. Starzl Transplantation Institute Transplantation in HIV+ Recipients Kidney 3 – Died of AIDS 6/8 (75%) – Normal graft function at 2-1/2 years and no HIV-related complications.

Thomas E. Starzl Transplantation Institute Transplantation in HIV+ Recipients Liver 90% mortality, 40% death from AIDS

Thomas E. Starzl Transplantation Institute Transplantation in HIV+ Recipients USRDS – HIV+ patients underwent renal transplantation 0.05% of transplants

Thomas E. Starzl Transplantation Institute Transplantation in HIV+ Recipients 1/3/5 Year Survival Patient Graft HIV+97%/83%/71% 81%/53%/44% HIV-95%/88%/78% 85%/73%/61% p<.05 at 3 years for GS, 5 years for PS/GS Main causes of death in HIV+ patients – infection, cardiovascular disease

Thomas E. Starzl Transplantation Institute Transplantation in HIV+ Recipients Acute Rejection HIV+ 50% HIV-48.4%

Thomas E. Starzl Transplantation Institute Transplantation in HIV+ Recipients Cyclosporine → Lower Incidence of AIDS 31% versus 90% at 5 years Inhibition of HIV Replication Binding to HIV -1 Gag protein

Thomas E. Starzl Transplantation Institute Transplantation in HIV+ Recipients HAART – 1996 Highly active antiretroviral therapy HIV+ ≠ AIDS

Thomas E. Starzl Transplantation Institute Transplantation in HIV+ Recipients If HIV+ ≠ AIDS Why deny transplantation to HIV+ patients?

Thomas E. Starzl Transplantation Institute Transplantation in HIV+ Recipients HIV-Associated Nephropathy (HIVAN) – Third leading cause of ESRD in African- Americans years of age HIV+/HCV+ → accelerated progression to ESLD

Thomas E. Starzl Transplantation Institute Transplantation in HIV+ Recipients HIV+ Patients on Dialysis Survival – USRDS 1 Year2 Years 58% 41% 32.7% One Year Mortality

Thomas E. Starzl Transplantation Institute Transplantation in HIV+ Recipients Inclusion Criteria Undetectable viral load (< 400 or <50 copies/ml) CD4 count >200 cells/mm 3

Thomas E. Starzl Transplantation Institute Transplantation in HIV+ Recipients Kumar – Hahnemann N- 40 2/01-1/04 (97% African-American) Survival 1 Year2 Years Patient 85% 82% Graft 75% 71% Viral load undetectable, CD4 count >400, no development of AIDS

Thomas E. Starzl Transplantation Institute Transplantation in HIV+ Recipients Hahnemann (Continued) Acute Rejection -22% Subclinical Rejection-29% Recurrent HIVAN-7.5%

Thomas E. Starzl Transplantation Institute Transplantation in HIV+ Recipients Stock – UCSF N – 14 Kidney – 10 Liver - 4

Thomas E. Starzl Transplantation Institute Transplantation in HIV+ Recipients UCSF (Continued) Kidney – 100% patient/graft survival Acute Rejection – 56% SRR – 30% Liver – 75% patient survival (One death to recurrent HCV) No rejection

Thomas E. Starzl Transplantation Institute Transplantation in HIV+ Recipients Hirose – UCSF 15 kidney recipients – 67% incidence of acute rejection, most with SRR

Thomas E. Starzl Transplantation Institute Transplantation in HIV+ Recipients Impact of Protease Inhibitors Markedly reduced calcineurin inhibitor requirements

Thomas E. Starzl Transplantation Institute Transplantation in HIV+ Recipients Pittsburgh N – 10 1 – PreHAART era, cyclo-based – deceased donor 4 – HAART era, TAC-based – deceased donors 4 – HAART era, Campath/TAC Monotherapy – living donors 1 – HAART era, Campath/TAC monotherapy – deceased donor

Thomas E. Starzl Transplantation Institute Transplantation in HIV+ Recipients Pittsburgh (Continued) Conventional Cyclo/TAC 100% one-year patient/graft survival but Currently 80% patient/20% graft survival (4 graft losses 3-8 years, 60% noncompliance) ACR – 80% (4/5) No AIDS, all viral loads undetectable

Thomas E. Starzl Transplantation Institute Transplantation in HIV+ Recipients Pittsburgh (Continued) Campath/TAC Monotherapy – 100% patient/graft survival Living donor – 0% ACR, all on spaced weaning 1 patient also had PAK Viral loads undetectable, CD4 counts initially low Deceased donor - noncompliant

Thomas E. Starzl Transplantation Institute Campath Pretreatment 38 y.o. Live Donor Kidney Graft

Thomas E. Starzl Transplantation Institute Campath Pretreatment Pancreas after Live Donor Kidney

Thomas E. Starzl Transplantation Institute Transplantation in HIV+ Recipients SRTR – Kidney Transplantation 1987 – – –

Thomas E. Starzl Transplantation Institute Transplantation in HIV+ Recipients SRTR (Continued) One Year Pt. Survival Graft Survival PreHAART93%75% HIV-93%82% HAART92%84% HIV-94%88%

Thomas E. Starzl Transplantation Institute Transplantation in HIV+ Recipients Multicenter NIH Trial In Progress

Thomas E. Starzl Transplantation Institute Transplantation in HIV+ Recipients 1.In the pre-HAART era, transplantation was uncommon, although the results with kidney transplantation were reasonable. 2.HAART has changed the natural history of HIV, and has led to an increased interest in transplantation. 3.A number of single centers have achieved reasonable outcomes after kidney transplantation. 4.Acute rejection may be more common in HIV+ recipients than HIV- recipients.

Thomas E. Starzl Transplantation Institute Transplantation in HIV+ Recipients 5.The interaction between protease inhibitors and calcineurin inhibitors is important. 6.Preconditioning with Campath followed by tacrolimus monotherapy may be a reasonable approach to immunosuppressive management in HIV+ recipients. 7.The current NIH-sponsored trial should provide more information about outcomes in HIV+ patients undergoing transplantation.